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METHODS PAPER
Novel Trial Design: CHIEF-HF
John A. Spertus , MD, MPH; Mary C. Birmingham , PharmD; Javed Butler, MD, MPH, MBA; Ildiko Lingvay, MD ;  
David E. Lanfear , MD, MS; Antonio Abbate , MD; Mikhail L. Kosiborod, MD, MS; Christina Fawcett , BA, PMP;  
Paul Burton , MD, PhD; C.V. Damaraju , PhD; James L. Januzzi , MD; John Whang , MD
BACKGROUND: The expense of clinical trials mandates new strategies to efficiently generate evidence and test novel therapies. 
In this context, we designed a decentralized, patient-centered randomized clinical trial leveraging mobile technologies, rather 
than in-person site visits, to test the efficacy of 12 weeks of canagliflozin for the treatment of heart failure, regardless of 
ejection fraction or diabetes status, on the reduction of heart failure symptoms.
METHODS: One thousand nine hundred patients will be enrolled with a medical record-confirmed diagnosis of heart failure, 
stratified by reduced (≤40%) or preserved (>40%) ejection fraction and randomized 1:1 to 100 mg daily of canagliflozin 
or matching placebo. The primary outcome will be the 12-week change in the total symptom score of the Kansas 
City Cardiomyopathy Questionnaire. Secondary outcomes will be daily step count and other scales of the Kansas City 
Cardiomyopathy Questionnaire.
RESULTS: The trial is currently enrolling, even in the era of the coronavirus disease 2019 (COVID-19) pandemic.
CONCLUSIONS: CHIEF-HF (Canagliflozin: Impact on Health Status, Quality of Life and Functional Status in Heart Failure) is 
deploying a novel model of conducting a decentralized, patient-centered, randomized clinical trial for a new indication for 
canagliflozin to improve the symptoms of patients with heart failure. It can model a new method for more cost-effectively 
testing the efficacy of treatments using mobile technologies with patient-reported outcomes as the primary clinical end 
point of the trial.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04252287.
Key Words: canagliflozin ◼ cardiomyopathy ◼ COVID-19 ◼ heart failure ◼ Kansas City Cardiomyopathy Questionnaire
Although cardiovascular disease remains the leading cause of death in the United States, wide-spread concerns have arisen about the costs, inefficiencies, 
and complexities of clinical trials. These costs, as well as 
barriers to regulatory approval, have dramatically attenu-
ated the introduction of new cardiovascular treatments.1 
As such, there have been calls for novel strategies to 
lower the costs of clinical trials.2,3 A large component (up 
to 50%) of these costs are the burden of data collec-
tion on sites, which has increased 3.6-fold from 1990 
to 2010.4 In response to the growing demands to make 
clinical trials more efficient, novel study designs have 
been implemented, from leveraging existing registries as 
the backbone of data collection5 to the use of electronic 
health records to identify, enroll, randomize and follow-up 
eligible patients.6
An additional significant threat to clinical trials is pro-
longed patient enrollment and deviations from planned 
follow-up in executing clinical trials. The ongoing coro-
navirus disease 2019 (COVID-19) global pandemic 
has proven to be a cataclysmic event for the conduct 
of clinical trials, significantly disrupting patient enrollment 
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Nonstandard Abbreviations and Acronyms
CHIEF-HF  Canagliflozin: Impact on Health Sta-
tus, Quality of Life and Functional 
Status in Heart Failure
DAPA-HF  Dapagliflozin and Prevention of 
Adverse Outcomes in Heart Failure
DEFINE-HF  Dapagliflozin Effects on Biomarkers, 
Symptoms and Functional Status 
in Patients With HF With Reduced 
Ejection Fraction
EF ejection fraction
  Empagliflozin Outcome Trial in 
Patients with Chronic Heart Failure 
and a Reduced Ejection Fraction
HF heart failure
HFpEF HF with preserved EF
HFrEF HF with reduced EF
KCCQ  Kansas City Cardiomyopathy 
Questionnaire




as patients and providers are all fearful of the risks of 
in-person site visits. Both the US Food and Drug Admin-
istration7 and a Heart Failure (HF) Collaboratory State-
ment8 have highlighted the need to prioritize the safety 
and well-being of HF trial participants and research team 
members, even if sacrificing protocol adherence.
Against this backdrop of a call for more efficient 
and cost-effective clinical trials and the need to maxi-
mize patient safety and convenience, we designed the 
CHIEF-HF trial (Canagliflozin: Impact on Health Status, 
Quality of Life and Functional Status in Heart Failure), 
which sought to directly engage participants without in-
person contact. An unplanned benefit of our trial design 
was its relevance and feasibility during the COVID-19 
pandemic, which had major disruptive consequences on 
traditional clinical trials. This report describes the novel 
methodological features of this decentralized trial.
METHODS
Evolving Role of Sodium-Glucose 
Cotransporter 2 Inhibitors in HF
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), which 
lower plasma glucose concentrations via increased urinary glu-
cose excretion, are a class of medications originally developed 
for the treatment of type 2 diabetes. They were also postulated 
to have a potential benefit in the treatment of HF.9,10 Several 
large cardiovascular outcome trials, and one large kidney out-
come trial, have demonstrated robust and consistent reduc-
tions in the risk of hospitalization for HF in patients with type 2 
diabetes.11,12 However, the overwhelming majority of patients in 
these studies did not have a history of HF, and those that did 
were not well-characterized. Therefore, although these trials 
established the efficacy of SGLT2i in preventing incident HF in 
high-risk patients, whether they could also treat patients with 
established HF was not well established until recently.
In the DAPA-HF trial (Dapagliflozin and Prevention of 
Adverse Outcomes in Heart Failure), a global randomized out-
come trial of dapagliflozin versus placebo in 4744 patients with 
HF and reduced ejection fraction (EF),13 patients treated with 
dapagliflozin (as compared with placebo) experienced a sig-
nificant 26% relative risk reduction in the primary composite 
outcome of cardiovascular death or hospitalization for HF, a 
benefit that emerged early and was consistent in both patients 
with and without type 2 diabetes.14 The recent publication of 
the EMPEROR-Reduced trial (Empagliflozin Outcome Trial in 
Patients with Chronic Heart Failure and a Reduced Ejection 
Fraction), which also demonstrated a significant reduction in 
cardiovascular death and HF hospitalizations, further empha-
sized the potential benefits of SGLT2i on clinical events.15 In 
addition, both DAPA-HF and EMPEROR-reduced significantly 
improved HF-related symptoms, as measured by the Kansas 
City Cardiomyopathy Questionnaire (KCCQ).15,16 The health 
status (symptoms, physical limitations, and quality of life) 
benefits of an SGLT2i were also addressed in DEFINE-HF 
(Dapagliflozin Effects on Biomarkers, Symptoms and Functional 
Status in Patients With HF With Reduced Ejection Fraction)—
the first randomized placebo-controlled trial of an SGLT2i 
that included the KCCQ as a part of the composite primary 
outcome.17 In that study, dapagliflozin significantly improved 
symptoms, physical limitations, and quality of life in patients 
with symptomatic HF with reduced EF after 12 weeks of treat-
ment. Furthermore, fewer patients treated with dapagliflozin 
(versus placebo) experienced a deterioration in health status, 
and significantly more patients treated with dapagliflozin had 
small, moderate, and large improvements in their health status. 
Collectively, these data support the benefits of dapagliflozin to 
improve the health status of patients with HF with reduced EF, 
but none of these agents are currently indicated for the clinical 
improvement in HF symptoms or for use in patients with HF 
with preserved EF (HFpEF). CHIEF-HF was designed to test 
the efficacy of canagliflozin on the health status outcomes of a 
broad spectrum of patients with HF.
Regulatory Shifts in Clinical End Points
Marked change has occurred in the Food and Drug 
Administration’s perspectives on clinical end points in HF trials 
for drug approval, including endorsement that patient-reported 
outcomes of reduced symptoms and improved function could 
support regulatory approval.18 Moreover, the Food and Drug 
Administration’s Center for Drug Evaluation and Research 
recently qualified the KCCQ as a clinical outcome assessment 
for drug approval and marketing.19 Collectively, the availability 
of a patient-reported outcome to serve as an approvable out-
come in clinical trials, coupled with the availability of mobile 
technologies to collect these data, have created an unprec-
edented opportunity to perform clinical trials at lower costs 
and with more efficiency than would otherwise be possible. 
Because of this, the CHIEF-HF trial was designed with the pri-
mary outcome being the Total Symptom Score of the KCCQ to 
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capture the benefits of canagliflozin over placebo on patients’ 
shortness of breath, fatigue, orthopnea, and edema.
Study Hypothesis
The primary hypothesis of the study is that canagliflozin is supe-
rior to placebo in improving HF symptoms within 12 weeks of 
treatment, as assessed by the KCCQ Total Symptom Score.
Study Methodology
CHIEF-HF was designed to be a decentralized (ie, no face-to-
face visits) US study with direct engagement of patients through 
a study website, electronic informed consent, direct home deliv-
ery of study medication, completion of the primary end point by 
a mobile application, and a Fitbit Versa 2 (San Francisco, CA) 
to monitor activity. Although clinical events were not included 
as a primary end point in this 3-month trial, these will be cap-
tured through claims data or patient self-report during the 
active 12-week treatment phase and the following 6 months. 
Collectively, this design allowed for the elimination of in-person 
site visits, a critical feature in enabling the study to launch in the 
midst of the COVID-19 pandemic and for reassuring partici-
pants who might be leery of coming to a hospital or clinic.
The study was designed, in conjunction with an Executive 
Steering Committee, by Janssen Scientific Affairs, LLC 
(Titusville, NJ) and PRA Health Sciences (PRA, Raleigh, NC). 
PRA is also leading the trial operations (with oversight by 
Janssen), including the creation of the web platform and mobile 
application (the primary means of data collection), randomiza-
tion and drug delivery, and facilitating a virtual study coordi-
nating center to support participant onboarding, questions, 
shipping the Fitbit and supplies, confirming receipt, and drug 
compliance. The organization of the study infrastructure is pro-
vided in Figure 1. The authors declare that all supporting data 
are available within the article.
Funding Sources
Funding for this study has been provided by Janssen Scientific 
Affairs and PRA Health Sciences.
Participant Inclusion and Exclusion Criteria and 
Process for Confirming Participant Eligibility
Potential participants are screened at participating US health 
systems, who all agreed to the use of a central Institutional 
Review Board (Advarra, Columbia MD). The complete inclusion 
and exclusion criteria are provided in the Data Supplement. In 
brief, participants must be 18 years or older with a diagnosis 
of HF, regardless of EF, to be eligible, irrespective of whether 
they have diabetes or not. A diagnosis of HF for potential par-
ticipants with a left ventricular EF of ≤40% was established by 
a primary diagnosis of HF or at least 2 medical visits (including 
virtual) with a diagnostic code for HF. For patients with a left 
ventricular EF >40%, use of a loop diuretic or an aldosterone-
receptor blocker was also required to improve diagnostic speci-
ficity. To support the mobile data collection of the KCCQ and to 
provide study support, patients were required to own a smart-
phone compatible with the app (either a Samsung S7 Galaxy or 
Apple iPhone 6 or later and the Fitbit), speak and read English, 
and be willing to wear a Fitbit for 9 months.
Those with any of the following within the timeframe listed 
before enrollment were excluded: currently taking an SGLT2i, 
having a history of diabetic ketoacidosis or type 1 diabetes, 
acute decompensated HF, advanced kidney disease (glomer-
ular filtration rate <30 mL/min or on dialysis), a diagnosis of 
recent hypotension, a history of atraumatic amputation or criti-
cal limb ischemia, planned major surgery, left ventricular assist 
device implantation, known allergy to canagliflozin, or pregnant, 
planning to become pregnant, or breastfeeding during the study.
To engage participants, sites are encouraged to develop a 
computable phenotype for the inclusion and exclusion criteria 
and to screen their electronic health record for potentially eligi-
ble participants. A range of options for contacting potentially eli-
gible participants are available for sites to adapt, based on their 
patient population and EHR capabilities. These include email, 
patient portal communications through the electronic medical 
record, traditional post, and phone calls. These invitations, all 
approved by the Central Institutional Review Board, encour-
age potential participants to visit the study website, to read and 
observe a video describing the study, and, if interested, to com-
plete an initial set of screening questions confirming initial eligi-
bility. If these criteria are met, potential participants opt-in to be 
contacted and evaluated for further eligibility. Participants who 
opt-in are then assessed by their respective health network for 
a full eligibility review before being scheduled for a virtual eCon-
sent call. This process reduces time invested by the sites so 
they only focus on those individuals interested in study partici-
pation. Candidates passing this initial screening are then invited 
to download the app in preparation for the virtual informed con-
sent call with a member of their health network authorized to 
obtain consent for CHIEF-HF and an independent observer 
from the virtual study coordinating call center. Once consent 
is obtained, the participant completes the KCCQ-23 to ensure 
that they have an Overall Summary score of ≤80 and are suffi-
ciently symptomatic to have the potential to improve from treat-
ment. The use of the KCCQ as an entry criterion ensures that 
patients are symptomatic and overcomes the well-documented 
limitations of relying upon clinician-assigned New York Heart 
Association classification.20 Once participants meet all study 
criteria, they are randomized by the Virtual Investigator.
Study Protocol and Execution
CHIEF-HF is a randomized, double-blind, placebo-controlled, 
decentralized, interventional, superiority study. Once participants 
with confirmed HF diagnoses undergo the virtual informed con-
sent process, provide documented consent to participate, and 
are determined to have a KCCQ Overall Summary score of ≤80, 
they undergo central randomization, stratified by the type of HF 
(HF with reduced EF [HFrEF] and HFpEF), to either canagliflozin 
100 mg or placebo for 12 weeks of drug exposure, followed by 
unblinding and a 6-month observational data collection period 
without study drug. Data collection throughout the study, as well 
as the assessment of medication compliance and reminders for 
study assessments, are being collected by the study-specific 
app. Examples of selected screenshots are shown in Figure 2.
The app includes an electronic version of the KCCQ-23 
that has been converted to an electronic format following the 
ISPOR ePRO (International Society for Pharmacoeconomics 
and Outcomes Research electronic Patient Reported Outcome) 
Good Research Practices Task Force recommendations.21 The 
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app also collects participants’ global assessments of change, 
their perceptions of the HF symptom severity, as well as a 
participant satisfaction survey at the completion of the trial to 
gain patients’ perspectives of participating in this decentral-
ized study. It also passively collects daily Fitbit data to directly 
quantify participants’ physical activity, including step count and 
floors climbed. The primary outcome, the KCCQ, will be col-
lected at baseline, weeks 2, 4, 6, and 12, and again at months 6 
and 9, with the 12-week assessment (the duration of random-
ized, double-blind drug exposure) being the primary outcome. 
The study will continue for an additional 6 months without any 
protocol-mandated treatment to collect participant follow-up in 
a real-world setting, including whether or not they begin open-
label SGLT2i treatment. Figure 3 provides an overview of the 
study design.
Study Outcomes
The primary assessment of efficacy is the 23-item KCCQ, which 
has extensive data supporting its validity, reliability, sensitivity to 
Figure 1. Overview of study infrastructure.  
(1) At the center of the trial is the participant, who is offered participation by their provider/health network and opts in after learning more on 
a central recruitment website. (2) Once their eligibility is verified by their health network, they interact with the Mobile Health Platform (mHP) 
to eConsent and complete a baseline KCCQ. (3)Upon KCCQ score review for eligibility, the participant is randomized through an Interactive 
Response Technology (IRT) system, which triggers direct-to-patient drug delivery. (4) The participant is also be shipped a Welcome Kit, including 
the Fitbit, from the Virtual Coordinating Center, which serves as participant liaison throughout the study for technology set-up and troubleshooting, 
call center support, safety reporting, and compliance monitoring. (5) All patient source data (ePROs, medication diaries) are collected via the mHP 
study app and Fitbit. (6) Upon consent and randomization, a token will be applied to patients to collect medical and prescription insurance claims. 
(7) All data will be integrated in and normalized within the PRA data cloud and translated into Study Data Tabulation Model (SDTM) data sets for 
analysis and submission to the FDA. IRT indicates Interactive Response Technology.
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clinical change, and association with other clinical events, such 
as HF hospitalization and death.22–27 The primary outcome of 
the CHIEF-HF study is the Total Symptom score of the KCCQ. 
The Total Symptom score is comprised of 7 items, 4 assessing 
symptom frequency, and 3 symptom severity or burden over the 
past 2 weeks and ranges from 0 to 100 points.
Secondary outcomes include a comparison of daily step 
counts acquired from the Fitbit, followed by these additional 
domain scores of the KCCQ: Physical Limitation, Quality of Life, 
the Clinical Summary (the average of Physical Limitation and 
Total Symptom scores), and the Overall Summary (the average 
of the Physical Limitation, Total Symptom, Social Functioning, 
and Quality of Life domains) scores. Exploratory analyses also 
include patients’ global ratings of change and symptom sever-
ity, health care resource utilization, daily floors climbed, and time 
to clinical events, including time to first HF hospitalization or 
death, as well as their satisfaction with the decentralized nature 
of the study. Adverse event reporting will also be collected 
through patient self-report.
An all-payer database (https://symphonyhealth.prahs.com/) 
will be used to monitor clinical events and health care utiliza-
tion, exploratory end points for this short-term trial, and to con-
firm patient eligibility. PRA (Symphony Health) has compiled a 
database of US medical and prescription claims that cover over 
300 million patients across all diagnoses, contains over 90% 
coverage of prescriptions dispensed, is geographically repre-
sentative and covers all payer types (Medicaid, Medicare, and 
Commercial Insurers). PRA’s patient claims data include some 
important patient demographics (gender, age), payer, as well 
as administrative diagnosis, treatment, and procedure codes 
that include date and location of service and physician name 
and address. Each deidentified patient in the data is assigned 
a longitudinally stable unique identifier that allows PRA to track 
deidentified patients longitudinally over time and across loca-
tions of care. PRA’s encrypted anonymized patient key links 
patient activities across many data sources to ensure individual 
patient-level data are anonymous and protected; consistent 
with US Health Insurance Portability and Accountability Act.
Despite the potential of the Symphony Health database, 
there are potential limitations due to the origin of claims data 
being transactional in nature. Specifically, deaths that occur 
outside of the hospital may be missed, if not captured by pay-
ers. Also, while extensive, PRA’s claims data may not capture 
complete activity of every enrolled patient. These caveats are 
documented in the claims data analysis plan, along with the 
recommendation of complementing patient activity captured 
through claims data by patient-reported outcomes and site’s 
electronic medical records. Importantly, the primary analyses 
Figure 2. Sample screenshots of data collection app.
KCCQ indicates Kansas City Cardiomyopathy Questionnaire. PGIs, Patient Global Impression - Severity
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of changes in KCCQ scores are collected directly from the 
patients as part of the trial.
Analytic Approach and Power
Analyses will be performed by intention to treat, with group allo-
cation based upon randomization, regardless of actual use of 
assigned medications. For the primary outcome, a mixed effect 
model of repeated measures, adjusting for study intervention 
(the primary variable of interest), stratification (HFrEF versus 
HFpEF), time by study intervention, and baseline KCCQ Total 
Symptom score will be performed. Although statistical signifi-
cance of this comparison with least-square means will test the 
primary hypothesis, the mean treatment group difference is not 
as clinically interpretable as the proportion of patients who clini-
cally improve or worsen.28 To support the clinical interpretabil-
ity of the observed mean differences, the proportion of patients 
who have a clinically small, but significant, moderate to large, and 
large to very large change in their health status, as defined by 
KCCQ changes of 5, 10, and 20 points, respectively, will be per-
formed.23,29–31 Mortality in this short-duration trial is expected to 
be low and to be comparable between groups and will be ignored 
in the primary analyses of mean differences in changes in KCCQ 
Total Symptom scores, but can be included in the responder 
analyses by assigning them to the lowest response (greatest 
deterioration) category. Should there be a >5% mortality rate and 
if it is unequally distributed between treatment arms, then joint 
modeling of survival and health status will be performed.32 The 
key secondary end point of step counts will be compared, if the 
primary analysis is significant at <5% type I error, using a 2-sided 
t test. The additional secondary end points of other KCCQ scores 
will be conducted in the same fashion as the primary outcome, 
using the baseline score of each domain in the model.
Sample size was determined for the primary outcome by using 
a 2-sample t test for continuous measures. The group mean 
differences of the KCCQ Total Symptom score that have been 
defined as clinically meaningful range from 3 to 5 points.29–31 
Accordingly, the study was powered to detect a 3-point change 
with 95% power, assuming a type 1 error of 5%, and a potential 
dropout rate of 5%. This led to a target sample size of 1900 
patients, randomized 1:1 to canagliflozin or placebo.
DISCUSSION
Demonstrating treatment benefit, ideally through the 
conduct of randomized clinical trials, is the foundation 
for advancing patient care. Yet, the cost and complexity 
of current clinical trials is proving to be a great impedi-
ment.1,2,33 A report by the Eastern Research Group exam-
ining key drivers for reducing the costs of cardiovascular 
phase 3 and 4 clinical trials identified lower-cost facilities 
or at-home testing (up to 10%–13% cost reduction), use 
of mobile technologies (up to 6%–14% cost reduction), 
use of electronic health records (up to 3-8% cost reduc-
tion) and simplified protocols (up to 2%–4% reduction) 
as the most important opportunities for improving the 
efficiency of clinical trials.34,35 By incorporating all of 
these features, CHIEF-HF has embraced multiple strat-
egies to model a more efficient approach to generating 
clinical trial evidence. It is also completely aligned with 
the recommendations of the National Academy of Medi-
cine, which recommends directly engaging health care 
systems in the research enterprise.33 Although designed 
before the onset of the COVID-19 pandemic, the novel 
design of CHIEF-HF highlights the urgency to explore 
novel approaches to generating evidence and possible 
benefits of innovative study design.
Figure 3. Overview of study design.
HFpEF indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; and KCCQ, Kansas City 
Cardiomyopathy Questionnaire.
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CHIEF-HF builds upon the slow evolution of novel 
clinical trials. A large advance was the leveraging of ongo-
ing clinical registries as the foundation for data collection, 
such that randomization of treatments could be done with 
minimal additional data collection.5 The recent publication 
of the ADAPTABLE (Aspirin Dosing: A Patient-centric 
Trial Assessing Benefits and Long-Term Effectiveness) 
trial methodology highlighted the use of electronic health 
records to identify, enroll, randomize, and follow eligible 
patients.6 Although CHIEF-HF similarly uses computable 
phenotypes to identify potentially eligible participants 
and refer them to a website for additional information 
about the trial, it also introduces a placebo-controlled 
randomized design, as opposed to the open-label, dose-
finding research question of ADAPTABLE. Although both 
CHIEF-HF and ADAPTABLE are using claims data with-
out adjudication to define clinical events, ADAPTABLE 
required a very large trial with which to be adequately 
powered for these events, whereas the primary outcome 
of CHIEF-HF is patient-reported symptoms, as captured 
by the extensively-validated KCCQ. In fact, the growing 
acceptance of patient-reported outcomes, including the 
recently qualified KCCQ, can be a harbinger of future 
such studies to accelerate the conduct of more affordable 
clinical trials to inform the benefits of new treatments.
There are sure to be unanticipated challenges with 
CHIEF-HF. For example, current standards for Good Clini-
cal Practice require that a disinterested party be present 
to witness the informed consent process. This requires a 
rather cumbersome process of coordinating a time dur-
ing which a potential participant, a site investigator, and an 
observer from the coordinating center can simultaneously 
be available to review the consent form, address ques-
tions, and confirm the identity of the participant with dual 
authentication, before obtaining an electronic signature. As 
comfort grows with virtual clinical trials, this process may 
be simplified by having patients view an online video and 
provide an electronic signature to the electronic consent 
and only arrange a video conference with the site investi-
gator if the potential participants have additional questions. 
In addition, the use of electronic activity monitors, although 
not new, is still early in their evolution, and defining the 
completeness of data capture and the interpretability of 
results require further study. Finally, requiring a smartphone 
and the ability to read and understand English can mini-
mize the diversity of the CHIEF-HF population, although if 
CHIEF-HF is successful, future studies can consider mak-
ing smartphones available, providing cards for data, and 
translating the platform to different languages.
An additional potential challenge with CHIEF-HF is 
the growing body of evidence showing improved survival 
or reduced hospitalizations with the use of SGLT2i for 
patients with HF.13,15 Although some might consider it 
unethical, in light of these data, to randomize patients to 
placebo, the sponsor and steering committee felt that this 
was reasonable based on several streams of logic. First, 
the half of enrolled patients assigned to placebo would 
only be exposed to inactive drug for 3 months, after which 
they could openly take an SGLT2i. Second, the proac-
tive screening process could accelerate their identifica-
tion and recognition by the health care system that they 
are candidates of an SGLT2i at the conclusion of the 
12-week trial. Finally, and most importantly, the transla-
tion of data, even as compelling as that of DAPA-HF and 
EMPEROR-Reduced,13,15 to clinical practice is notoriously 
slow and inefficient. In fact, a contemporary HF registry 
reported that even among patients with diabetes, <5% are 
treated with SGLT2i.36 By being enrolled in CHIEF-HF, all 
patients will have been identified as potential candidates 
for treatment and educated about the potential benefits 
of treatment so that their providers could consider adding 
these medications to their HF regimen.
CHIEF-HF also provides an example of moving away 
from simply enrolling a subset of patients based on their 
EF. This approach was chosen because although patients 
are clearly aware of their symptoms, function, and quality 
of life, they are not aware of their left ventricular physi-
ology. Focusing the primary outcome on patients’ health 
status, for which the KCCQ’s validity and prognostic abil-
ity has been shown to be similar in patients with HFrEF 
and HFpEF, further supports the appropriateness of com-
bining these HF phenotypes in a patient-centered trial.23 
Moreover, evidence is accumulating that the clinical ben-
efits of SGLT2i is similar in patients with both HFrEF and 
HFpEF, as seen in the recent SOLOIST-WHF (Effect of 
Sotagliflozin on Cardiovascular Events in Patients With 
Type 2 Diabetes Post Worsening Heart Failure) trial, 
although the KCCQ data has not yet been published.37 
Although the expectation is of similar benefits across the 
spectrum of HF, randomization is stratified by EF and for-
mal tests of an interaction of treatment benefit by HFrEF 
and HFpEF will establish this more definitively.
In light of the growing therapeutic options for HF treat-
ment to reduce hospitalizations and mortality,13,15,38–41 
improving patients’ health status, their symptoms, func-
tion, and quality of life, may become a distinguishing fea-
ture in deciding which treatment might be started after 
beta-blockade and inhibition of the renin-angiotensin-
aldosterone axis. Trials, like CHIEF-HF, which explic-
itly quantify these benefits have the ability to provide 
important information for clinicians to support shared 
decision-making with patients.42 Moreover, innovations in 
the conduct of such trials, such as the methods exempli-
fied in CHIEF-HF, can model ways to more efficiently 
generate evidence and accelerate the evidence-base of 
guidelines and care in many other therapeutic areas.43
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